Luvox

It or not, but i saw the pdoc yesterday & he added luvox to my vivactil.
Prevention may be typically divided into: primary, where the goal is to prevent the onset of the disease, selecting healthy cohorts at high risk for environmental or lifestyle or familial genetic factors; secondary, to treat a population with a premalignant condition or an in situ neoplasia thereby blocking its evolution to cancer; and tertiary, to protect against second primary tumors in subjects previously cured for a cancer. An essential aspect is the definition of the appropriate target population by selecting and identifying the criteria for high-risk subjects in order to increase the risk benefit ratio of the intervention treatment. An important target is represented by subjects at high risk for familial and genetic factors. Knowledge on the various aspects of genetics has grown enormously and the recent possibility to test for genetic mutations predisposing to breast, ovarian, colorectal or other cancers is leading to an increasing impact of molecular data in clinical management of selected mutation carriers. However, we must be aware of the current limitations of the molecular diagnosis and the complexity of the multidisciplinary management of genetically predisposed subjects.

Loss of appetite and weight loss is less of a concern with fluvoxamine than with fluoxetine and folic.

In total, 93, 305 of 158, 530 patients received an SSRI as their first antidepressant treatment Table 1 ; . SSRI users were slightly younger than non-SSRI users Table 1 ; , although more than 95% of all SSRI and non-SSRI users were aged over 18. Approximately two-thirds of all incident users of both SSRIs and non-SSRIs were female, with more females among non-SSRI users. SSRI users were more likely to have a history of depression prior to initiation of therapy, and less likely to have prior anxiety alone. SSRI users also tended to be registered on the GPRD for longer periods prior to the first antidepressant prescription. Of the patients first prescribed an SSRI, 30% received Paroxetine as their first treatment, 42% received Fluoxetine, 11% received Sertraline, 0.7% received Fluvoxamine and 16% received Citalopram Escitalopram Table 2 ; . Although the large sample sizes suggested statistically significant differences between Paroxetine and other SSRIs in terms of age, gender, length of history and most recent diagnosis, there appeared to be few notable differences between products in the age or gender of patients at the time of first prescribing. Paroxetine and Citalopram users were more likely to have a history of anxiety prior to initiation of therapy relative to users of Fluoxetine, Sertraline or Fluvoxamine. Statistical comparisons also suggested statistically greater length of prior history among users of Paroxetine vs. other SSRIs. Drug on Patent NIZEROL Zoladex Daypro Norcuron Vancenase AQ Vancenase Plain Vanceril Generic Name Ketaconazole Goserelin acetate Oxaprozin Vecuronium bromide Beclo methasone dipropionate Beclo methasone dipropionate Beclo methasone dipropionate Unasyn Versed Inj. Nicoderm CQ Ampicillin Sod sulbactam Sod. Midazolam Nicotine Triamcinalone acetonide Luvox Fluvoxamine maleate Iohexal Terbinafine HCl Beclomethazone U.S. phillips Roche Syntex SKB RPR Pfizer 11 18 97 NCE 12 05 99 Omnipaque Lamisil cream Beconase Sanofi Novartis 12 30 06 Allen & Hanburys 12 21 99 U-73 NCE 130 110 D-7 11 18 99 ScheringKey 10 29 99 ScheringPlough 10 29 99 ScheringPlough Searle Monsanto Organon and fosinopril.
Journal Entry: 1: 15 p.m. What's happening?! "Mr. Zappy" has opened the door in my head and seems to be setting up shop. No "super zaps, " but they definitely have arrived. Feel slushy, feel like my "brain spring" is winding down. Have slight out-of-body feeling. If I stare at one thing for too long it seems like I start "shifting away" from it in short, almost calibrated frames. Don't know how else to describe "it." Hope this will pass, don't have the doc's pager # so can't check with him for advice -- take a little more Paxil? Wife's suggestion. ; Uh, NOT! Maybe Luvox. Going to play it by ear. Just got one more week of Luvox -- supposed to cut it to 12.5 m.g. but cut them up "fat" so I will have an even more gradual taper. Having to do all of this is just f * cking NUTS. Journal Entry: 1: 50 p.m backyard to get dog. Vision blurry. Journal Entry: 5: 50 p.m. "It ain't over till its over." Took one arthritis strength BC powder and 750 m. g. aspirin. Was going to melt into couch but went to look at furniture in Dalton with wife. My head has had star billing in the "Electric Light Orchestra." A non-stop headzappin zap fest. But not so intolerable as to chase me back to the Paxil pill bottle to God, help ; make them stop. Felt like "Luke Skywalker" as we strolled through a furniture warehouse, my feet on the ground and head in the clouds. Sensation in head like when you go to dentist and take many deep lungfuls of nitrous oxide. Felt like a couple of ratchets in the gears of reality have stripped or slipped. I'm home now, still in zap zone -- every time I shift eyes I get a zap. Still feel -- still have nitrous oxide feeling. Peculiarly, zaps are most intense if I shift eyes left to right or vice versa. So . what's next. Distressing thought. Is my withdrawal phase just really cranking up or I close to the finish line -- just don't know. Journal Entry: 6: 40 p.m. Zaps seem a little better, i.e. less intense and frequent. Feel very edgy, like I might snap at the slightest provocation. My legs feel heavy and are aching, as well as my feet. This afternoon -- I've got the image now -- I felt like my head was one of those electric bug zappers with the weird purple light ; people put out in their yards during summer. Journal Entry: 7: 20 p.m. OH FUCK THIS SH * T! I am, I just can't think of what to say. Days would be one thing -- but weeks. Zap, zap, ears are ringing, irritable, achy, feet feel hot. I hoping Luvox dose tonight will knock some of this out. Going to use massager on feet in a minute -- they feel hot and crampy. Journal Entry: 8: 20 p.m. Strange enough my power "thumper" massager on my feet seems to have helped. Still getting blasted by the zaps -- on a scale of one to ten I'd rate. JMCP publishes peer-reviewed original research manuscripts, subject reviews, and other content intended to advance the use of the scientific method, including the interpretation of research findings in managed care pharmacy. JMCP is dedicated to improving the quality of care delivered to patients served by managed care pharmacy by providing its readers with the results of scientific investigation and evaluation of clinical, health, service, and economic outcomes of pharmacy services and pharmaceutical interventions, including formulary management. JMCP strives to engage and serve professionals in pharmacy, medicine, nursing, and related fields to optimize the value of pharmaceutical products and pharmacy services delivered to patients. JMCP employs extensive bias-management procedures intended to ensure the integrity and reliability of published work and geodon.

The term hallucinogen is used to describe drugs that produce distortions of reality. Hallucinogens are sometimes called "psychedelic drugs." Hallucinogens dramatically affect perception, emotions and mental processes. They distort the senses and can cause hallucinations. Hallucinations are sensory images similar to dreams or nightmares; a person may see, taste or hear things that are not really present. Those who are grieving often express a wish to "skip" the holidays altogether. The explosion of emotions that is normal as the holidays approach, may manifest in physical symptoms that bring them to a doctor's office. As a grief counselor, I encourage clients to reach out to their physician for medical assessment to begin the process of taking care of themselves, something they often neglect while providing care of a loved one. Physicians and their staff can help normalize a griever's experience by explaining their grief not as something to be feared but as a normal reaction to living and loving in life. Appropriate support of the bereaved patient calls first for understanding of the difference between normal and complicated grieving and the appropriate interventions. See Wolfelt chart on page 2 ; In addition to clinical depression, complicated grieving may manifest in anxiety, eating disorders, extended insomnia, panic attacks and symptoms of post traumatic stress disorder PTSD ; . Many variables play a part in an individual's ability to cope with grief. These include length of illness, type of death, support systems, concurrent crisis, multiple losses, history of mental illness, history of or current abuse of substances. All of these and ziprasidone. Lotrisone .T-31 LOTRONEX .T-34 lovastatin.T-27 LOVENOX .T-50 loxapine succinate.T-18 Loxitane .T-18 Lozol .T-27 Ludiomil.T-10 Lufyllin .T-57 LUMIGAN.T-54 LUNESTA .T-59 Lupron.T-39 LUPRON DEPOT.T-40 LUPRON DEPOT-PED.T-40 Luvox .T-10 LYRICA .T-9 LYSIPLEX.T-50 LYSODREN .T-39 Macrobid .T-5 Macrodantin .T-5 MAGAN .T-1, T-13 MAGNEBIND 400 RX.T-50 magnesium chloride .T-60 magnesium salicylate .T-1, T-13 magnesium sulfate.T-60 MAJOR INSULIN SYRINGE.T-50 MALARONE.T-17 Mandelamine.T-4 MANDOL IN DEXTROSE.T-6 mannitol .T-27, T-54 maprotiline hcl .T-10 MARCAINE W EPINEPHRINE.T-3 MARINOL.T-11 MARPLAN .T-10 MATULANE .T-14 MAVIK .T-28 MAXAIR AUTOHALER.T-58 MAXALT .T-13 MAXALT MLT .T-13 MAXAQUIN .T-8 MAXIPIME .T-4 Maxitrol.T-54 mebendazole.T-16 meclizine hcl.T-11 meclofenamate sodium.T-1, T-13 Meclomen .T-1, T-13. Synthon B.V., Postbus 7071, NL-6503 Fluvoxaminemaleaat 25 mg, tablets 25 mg GN Nijmegen and glipizide. It is important to check with your doctor before combining generic imitrex sumatriptan ; with the following: drugs classified as mao inhibitors, including the antidepressants nardil and parnate ergot-containing drugs such as cafergot and ergostat fluoxetine prozac ; fluvoxamine luvox ; paroxetine paxil ; sertraline zoloft ; additional information do not drive, use machinery, or do anything that needs mental alertness until you know how generic imitrex sumatriptan ; affects you. Dedication and Acknowledgment This book is dedicated to two brilliant and brave men, Professor Roger Wyburn-Mason, who one day should receive the Nobel Prize in Medicine, and Dr. Jack M. Blount, who should at least receive the Congressional Medal of Honor for bravery in the face of hostile forces; with special mention also for Dr. Robert Bingham whose open-mindedness and foresight brought Professor Roger Wyburn-Mason's work overseas, John R.A. Simoons, Ph. D., for persistence in bringing this work to attention of academia and drug manufacturers, Dr. Archimedes A. Concon, for vision in and grisactin. In vitro data show that CYP2D6 has been shown to be non-inducible and that duloxetine may inhibit CYP3A, CYP1A2, or CYP2C9 at concentrations substantially higher than those anticipated in the clinical setting. It is unlikely that enzyme induction would occur clinically. In vivo drug-drug interaction studies have been carried out with CYP2D6 substrates desipramine and tolterodine ; , CYP2D6 inhibitors paroxetine ; , CYP1A2 substrates theophylline ; , CYP1A2 inhibitors fluvoxamine ; , and other drugs and substances likely to be co-administered with duloxetine lorazepam, temazepam, ethanol and antacids ; . Duloxetine has shown to be a moderate CYP2D6 inhibitor 3-fold increase in the overall exposure to desipramine and 2-fold increase to tolterodine ; . Similarly, paroxetine CYP2D6 inhibitor ; increases duloxetine overall exposure by 60 %. Fluvoxamine, a potent CYP1A2 inhibitor, increases the exposure of duloxetine more than 5-fold ; No significant interactions with benzodiazepines and antacids have been found. The SPC clearly reflect these findings. Additional data for CYP2C19 was submitted for this application. It is agreed that these isoforms represent a small part of the metabolism of commonly prescribed drug. On the other hand, since CYP2C8 isoenzymes might be involved in the occurrence of clinically important interactions due its inhibition, e.g. by gemfibrozil, an in vitro study investigating the effect of duloxetine on the metabolism of a CYP2C8 substrate is to be performed. Conclusion on human pharmacokinetics Duloxetine is a drug with highly variable pharmacokinetics and many factors affect the systemic exposure. From the presented data, gender, age, food, renal and hepatic function, smoking status, CYP2D6 status and drug-drug interactions are all factors affecting the plasma levels of duloxetine. Interindividual differences in plasma concentrations of 1-acid glycoprotein AAGP ; may also contribute to the variability. It has been discussed whether when considered isolatedly, none of these factors except ESRD and liver cirrhosis ; is expected to induce clinically relevant changes in duloxetine PK requiring dosing adjustments. Pharmacodynamics Six studies were designed to evaluate pharmacodynamics in healthy volunteers. Four of them were aimed to assess pharmacodynamyc effects and safety during treatment with increasing doses of duloxetine and the other two evaluated pharmacodynamic interactions with ethanol and lorazepam. No clinical data on primary pharmacology are provided. This was considered acceptable, as there are no validated PD models for MDD. Study Code SBBN Design. Approximately 37 million Americans suffer with sinusitis symptoms annually, making it one of the most common reasons for visits to primary care physicians. "Sinusitis considerably reduces a patient's quality of life, " says Ray Weiss, M.D., Sinus Center of the South. In addition, sinusitis is the fifth most Frontal Sinus common condit ion for wh ich Sphenoid Sinus a nt ibiot ic s a prescribed in the Maxillary Sinus U n ited States a nd is respons ible for t ot a health care-related expenditures Sinusitis patient with infected left frontal exceeding $ 8.1 and left maxillary sinuses billion per year. With such a large patient population and the societal implications, M.D. News assembled a panel of leading ENT physicians to shed some light on this complex disease, its care continuum and recent advancements in treatment. A WIDE SPECTRUM OF OVERLAPPING SIGNS AND SYMPTOMS Sinusitis refers to an inflammation of the sinus lining that can be associated with bacterial or viral infections and structural issues, like sinus ostia blockages. If the sinus ostium is closed, normal mucus drainage may not occur, predisposing the sinuses to infection and inflammation. The condition is considered acute when symptoms last less than four weeks and chronic when they persist for more than 12 weeks. MATCHING PATIENTS' SYMPTOMS TO THEIR CONDITION Experts don't necessarily agree, however, on the definition and pathophysiology of sinusitis. Some feel that rhinitis and sinusitis are linked conditions and have introduced the term rhinosinusitis, while others feel rhinitis and sinusitis are distinct and griseofulvin. Thomas herzog , division of gynecologic oncology, washington university school of medicine, 4911 barnes hospital plaza, st louis, mo 63110, usa available online 23 january 200 corresponding author. Source: medicinenet gastroparesis - gastroparesis means paralysis of the muscles of the stomach and gabapentin. Cheap luvox online Lexapro adderall ambien ativan clonazepam cymbalta celexa effexor glutathione haldol lexapro paxil-seroxat prozac sarafem wellbutrin zoloft ritalin risperdal zyprexa strattera sleep problems depression omega 3 how to taper off medications how to lose weight caused by antidepressants pms answers and solutions click here home lexapro pms answers and solutions how to taper off medications antidepressants adapin anafranil asedin aventyl celexa cymbalta desyrel effexor elavil endep imipramine lexapro luvox norpramin paxil prozac sarafem sinequan wellbutrin zoloft benzodiazepines alprazolam xanax ativan clonazepam - klonopin diazepam - valium adhd medications adderall dextrostat ritalin strattera anti-psychotics haldol risperdal - risperidone zyprexa how to taper off medication in defense of physicians weight gain caused by antidepressants , how to lose it sleep problems anxiety omega 3 stress depression effexor withdrawal. Buy luvox online Tracking times of medications, withdrawal, and headache, using the headache diary, is usually very helpful in diagnosis and gatifloxacin and luvox. Hope he wises up before its to late wot 08-26-04 kartmom being who i with the things i have done i can say that your son's drug use abuse carries with it far more things than just using the drugs. Table 3. Colorectal Neoplasia Prevention Trials Evaluating Dietary Fat and Fiber and micronase. Not all interactions are clinically significant. An interaction is more likely to be clinically significant if: A drug has a narrow therapeutic window. A drug has serious, dose dependent toxicity. The change in serum drug level is at least 30%. There are two basic types of interactions: Pharmacokinetic what body does to drug ; : occurs with changes to the absorption, distribution, metabolism or excretion of a drug. For example, Pglycoprotein is a membrane transport pump found in many areas of the body including the GI tract, blood brain barrier and kidneys, which limits the distribution of certain drugs into tissues. It acts like a nightclub bouncer, preventing certain drugs from crossing the membrane i.e. into the bloodstream from the gut or past the blood brain barrier ; . Inhibition of Pglycoprotein by a drug facilitates the entry of certain drugs into tissues. Pharmacodynamic what drug does to body ; : can be thought of as the additive effects of two drugs e.g. concomitant metoprolol and verapamil therapy will both slow the heart rate. There are two major types of drug metabolism both occur primarily in the liver ; : Phase I reactions cytochrome P450 enzyme system ; : There are over 100 different P450 families and these enzymes are responsible for metabolizing both exogenous and endogenous substances. The major P450 systems involved in drug metabolism are shown in the pie chart below. CYP 3A4 is the most common enzyme system involved in interactions. Phase II reactions: acetylation, methylation glucuronidation, sulfation. Overall, the goal of drug metabolism is to take a relatively non-polar substance and make it more polar, thus facilitating its excretion in the urine. Phase I reactions will involve exposing an oxygen moiety on the drug molecule oxidation-reduction type of reaction ; . Then a Phase II reaction can act on this moiety and, in the process, stick on a polar side group. The drug is then more readily excreted by the kidneys. The following are some common medications involved in P450 pathway: CYP 450 inhibitors: clarithromycin, erythromycin, protease inhibitors nelfinavir, ritonavir, indinavir ; , amiodarone, fluvoxamine, fluoxetine, paroxetine, diltiazem, verapamil, itraconazole, ketoconazole, isoniazid 2C9 ; , fluoroquinolones, quinidine. CYP 450 inducers: rifampin, phenobarbital, phenytoin, carbamazepine, isoniazid 2E1 ; . CYP 450 substrates: theophylline, amitriptyline, phenytoin, phenobarbital, propafenone, cyclosporine, tacrolimus, clarithromycin, erythromycin, quinidine, alprazolam, diazepam, triazolam, ritonavir, indinavir, saquinavir, amlodipine, nifedipine, felodipine, verapamil, diltiazem, clozapine. Information added to indicate that cysteamine is teratogenic and fetotoxic in rats. Some of the teratogenic effects include cleft palate, kyphosis, heart ventricular septal defects, microcephaly and exencephaly. Pediatric dosing information added to the labeling including dosing and dilutions. Information added regarding potential drug interactions with inhibitors and inducers of the cytochrome P450 3A4 isoezyme. Post-marketing adverse effects added to the labeling include edema, tachycardia, weight loss, and blurred vision. The following statement has been added to the dosing section: "Opioid withdrawal symptoms such as nausea, vomiting, diarrhea, anxiety, and shivering ; are possible in some patients after conversion or dose adjustment." Teratogenicity information from various animal models shows hydroxyurea to be a potent teratogen. Reported effects include partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, and missing lumbar vertebrae. Postmarketing adverse effects: alopecia, hyponatremia. Check with your doctor as soon as possible if any of the following side effects occur: more common burning, crawling, or tingling sensation of the skin swelling at the site of application worsening of eczema and itching rare fever symptoms of overdose abdominal pain and swelling blurring of vision convulsions seizures ; decreased awareness or responsiveness difficulty in breathing difficulty in passing urine dizziness, fainting, or lightheadedness drowsiness enlarged pupils excessive dryness of mouth extremely high fever or body temperature extremely low body temperature fast heartbeat increased or excessive unconscious or jerking movements incurable constipation irregular heartbeat unconsciousness vomiting weak pulse some side effects may occur that usually do not need medical attention. For the prediction of nonresponse to drug therapy a logistic regression analysis was carried out for all significant baseline variables. Subsequently a best fitting model was made with all significant variables using logistic regression with backwards elimination. As criterion for variable selection the likelihood-ratio test was used. Results Differences at baseline Of the 30 patients who received active medication brofaromine or fluvoxamine ; there was one patient in the fluvoxamine group who dropped out in the second week due to severe side effects. This patient was not included in the analysis. The response rates did not significantly differ between the drug groups on any of the criterion variables Table 1 ; . Three variables were different between the drug groups: the mean score SD ; on the HAS was higher in the fluvoxamine group 20.9 3.4 ; compared to the brofaromine group 17.9 3.9 ; F 4.78; df 1, 27; p 0.038 ; , less patients in the fluvoxamine group had been treated previously with benzodiazepines 7.1% vs. 46.7%; Fisher exact test; p 0.035 ; and more patients in the fluvoxamine group had been treated previously with behavioural therapy 57.1% vs. 13.3%; Fisher exact test; p 0.021 ; . The criterion variable `50% reduction of the SPS-fear' did not differentiate responders from nonresponders Table 2 ; . Most of the differences between responders and nonresponders were evident with `entered the follow up' as criterion variable. There were no significant differences between responders and nonresponders to drug therapy on demographic variables like sex, age or duration of illness. Nonresponders had a significantly higher heart rate at baseline. The systolic blood pressure of nonresponders was also higher, and this difference was significant on three criterion variables. The diastolic blood pressure was also elevated in nonresponders, but this difference was only evident with `entered the follow-up' as criterion variable. Nonresponders also had a higher baseline score on the HAS, the HDS and the anxiety and interpersonal sensitivity subscores of the SCL-90. Most of the illness characteristics did not significantly differentiate between responders and nonresponders. Only one variable was found to significant. Of the patients with less than 50% improvement on the SPS-avoid 47.6% had a family history of SP, while none of the responders had such a history. The response rates of the patients on the criterion variables differed considerably. With `entered the follow-up' as criterion variable 72.4% of the patients were considered responders, while with `50% reduction of the SPS-avoid' as criterion variable only 27.6% were considered responders. There was a significant correlation between 50% improvement on the SPS-fear and the SPS-avoid Table 3 ; . The correlation between 50% improvement on the HAS and the SPSfear just failed to reach statistical significance p 0.061 ; . `Entered the follow-up' as criterion variable was uncorrelated with the other criterion variables. Board to take no disciplinary action in regard to the physician. Each case of prescribing for pain will be evaluated on an individual basis. The physician's conduct will be evaluated to a great extent by the treatment outcome, taking into account whether the drug used is medically and or pharmacologically recognized to be appropriate for the diagnosis, the patient's individual needs including any improvement in functioning, and recognizing that some types of pain cannot be completely relieved. 5 ; If the provisions as set out in paragraphs 1 ; - 4 ; of this section are met, and if all drug treatment is properly documented, the board will consider suchpractices as prescribing in a therapeutic manner, and prescribing and practicing medicine in a manner consistent with public health and welfare. 6 ; Quantity of pharmaceutical and chronicity of prescribing will be evaluated on the basis of the documented appropriate diagnosis and treatment of the recognized medical indication, documented persistence of the recognized medical indication, and properly documented follow-up evaluation with appropriate continuing care as set out in this chapter. 7 ; A physician may use any number of treatment modalities for the treatment of pain, including intractable pain, which are consistent with legitimate medical purposes. 8 ; These rules shall be construed so as to apply to the treatment of acute pain with dangerous drugs or controlled substances for purposes of short-term care. Source: The provisions of this 170.3 adopted to be effective April 7, 1995, TexReg 2211 and folic. Enalapril maleate ENBREL InJ, SP, Par endocet enulose EPIPEN, -JR InJ, QLL epitol ergoloid mesylates ERYC G erythromycin base erythromycin sulfisoxazole estradiol QLL ETHMOZINE ethosuximide etidronate disodium EVISTA EXELON EXJADE SP famotidine InJ FAMVIR QLL FAZACLO FEMARA fentanyl citrate InJ fexofenadine hcl QLL FLOMAX FLONASE QLL FLOVENT -HFA QLL fluconazole 150 mg tablets ; QLL fludrocortisone acetate flunisolide QLL fluocinonide-e fluorometholone fluoxetine hcl fluphenazine hcl fluvoxamine maleate QLL FML FORTE -S.O.P. -S LIQUIFILM FORADIL AEROLIZER QLL FOSAMAX -PLUS D QLL furosemide InJ FUZEON InJ, SP, Par gabapentin gauze pad, 2" x 2" gemfibrozil GEODON QLL GLEEVEC SP, Par glipizide -er GLUCAGON EMERGENCY KIT glyburide -micronized glycolax haloperidol heparin sodium InJ HUMALOG InJ HUMIRA InJ, SP, Par hydrochlorothiazide hydrocodone acetaminophen. Paracetamolum + Acidum ascorbicum + Dextromethorphani hydrobromidum Paracetamolum + Acidum gran. for oral sol. ascorbicum + Pheniraminum Paracetamolum + tab. Pseudoepherinum + Chlorphenaminum Fluvoxaminum film-coated tab. Fluvoxaminum film-coated tab. When you were on luvox , i see it is rx'd for ocd ; were you at a dose even. It is a powerful antioxidant that has a number of health-giving, disease preventing properties. The relationship of the sites of treatment failure to the initial sites of metastatic disease in stage II and III patients is outlined in Table 3. Overall, 38% of patients had new sites of disease at the time of treatment failure; five 13% ; experienced recurrence at new sites only. Of these five recurrences in new sites only, one each occurred in the lung, mediastinum, liver, brain, and axillary lymph nodes.

© 2006-2007 Online.atspace.us -All Rights Reserved.